Trial Search Results

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. Comparing results of imaging procedures, such as PET scans and CT scans, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This phase II clinical trial studies how well chemotherapy based on PET/CT scan works in treating patients with stage I or stage II Hodgkin lymphoma.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

American College of Radiology Imaging Network

Collaborator: Eastern Cooperative Oncology Group

Stanford Investigator(s):

Intervention(s):

  • Drug: ABVD Induction
  • Drug: Escalated BEACOPP
  • Drug: Standard BEACOPP
  • Diagnostic Test: PET
  • Radiation: INRT

Phase:

Phase 2

Eligibility


DISEASE CHARACTERISTICS:

   - Histologically proven classical Hodgkin lymphoma subclassified according to the World
   Health Organization (WHO) Classification of Tumors, 4th edition (2008)

      - Nodular lymphocyte-predominant Hodgkin lymphoma is excluded

   - Patients must have clinical stage IA, IB, IIA, or IIB disease

      - Patients with "E" extensions will be eligible if all other criteria have been met

   - Patients must have a mediastinal mass > 0.33-cm maximum intrathoracic diameter on
   standing postero-anterior chest x-ray or measuring > 10 cm in its largest diameter on
   axial CT images

   - Bone marrow biopsy is required

PATIENT CHARACTERISTICS:

   - ECOG performance status 0-2

   - ANC ≥ 1,000/μL

   - Platelet count ≥ 100,000/μL

   - Hemoglobin ≥ 10 g/dL

   - Serum creatinine ≤ 2 mg/dL

   - Direct bilirubin ≤ 2 mg/dL

   - AST/ALT ≤ 2 times upper limit of normal

   - Not pregnant or nursing

   - Negative pregnancy test

   - Women of childbearing potential and sexually active males must be strongly advised to
   use an accepted and effective method of contraception

   - No "currently active" second malignancy other than non-melanoma skin cancers

      - Patients are not considered to have a "currently active" malignancy if they have
      completed therapy and are considered by their physician to be at less than 30%
      risk of relapse

   - LVEF by ECHO or MUGA normal unless thought to be disease related

   - DLCO ≥ 60% with no symptomatic pulmonary disease unless thought to be disease related

   - Patients with a history of intravenous drug abuse, or any behavior associated with an
   increased risk of HIV infection, should be tested for exposure to the HIV virus, and
   an HIV test is required for entry on this protocol

   - HIV-positive patients are eligible if they have CD4 counts ≥ 400/mm³ and are on
   concurrent antiretrovirals

      - Patient HIV status must be known prior to registration

      - HIV-positive patients must not have multi-drug resistant HIV infections; CD4
      counts < 400/mm³; or other concurrent AIDS-defining conditions

PRIOR CONCURRENT THERAPY:

   - No prior treatment (chemotherapy or radiation therapy) for Hodgkin lymphoma

   - Concurrent antiretroviral therapy for HIV-positive patients (CD4 counts ≥ 400/mm³)
   allowed

Ages Eligible for Study

18 Years - 120 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting